Developability of Biotherapeutics (eBook, PDF)

Computational Approaches
Redaktion: Kumar, Sandeep; Kumar Singh, Satish

• Format: PDF

Produktbeschreibung

Biopharmaceuticals are emerging as frontline medicines to combat several life-threatening and chronic diseases. However, such medicines are expensive to develop and produce on a commercial scale, contributing to rising healthcare costs. Developability of Biotherapeutics: Computational Approaches describes applications of computational and molecular

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Taylor & Francis eBooks
• Seitenzahl: 315
• Erscheinungstermin: 18. November 2015
• Englisch
• ISBN-13: 9781482246155
• Artikelnr.: 44195096

Autorenporträt

Sandeep Kumar, PhD, is a senior principal scientist at Pfizer, Inc. in the Biotherapeutics Pharmaceutical Sciences group, working on computational modeling and developability risk assessments of a wide variety of biotherapeutic drug candidates, including monoclonal antibodies, antibody-based therapeutics, fusion proteins, vaccines, and antibody-drug conjugates. He earned his PhD in computational biophysics from the Molecular Biophysics Unit of the Indian Institute of Science, Bangalore, India, and performed postdoctoral research on proteins at the National Cancer Institute in Frederick, Maryland, a part of the National Institutes of Health. He has been an assistant professor (research-track) at Georgetown University Medical Center, Washington, DC; an assistant professor at the Indian Institute of Technology, Kanpur; and an associate research scientist at Johns Hopkins University, Baltimore, Maryland. He has more than 17 years of experience in computational protein sciences. He has contributed more than 60 research papers, review articles, and book chapters, has delivered more than 40 invited talks, and has chaired sessions of several conferences. He has won several fellowships and awards, including a Fogarty visiting scientist fellowship at NIH and the 2014 Ebert Prize from the American Pharmacists Association. He has also mentored several graduate students and postdoctoral scientists. Satish Kumar Singh, PhD, is a research fellow at Pfizer, Inc. in the Biotherapeutics Pharmaceutical Sciences group, and an adjunct professor of the Department of Physical Pharmaceutical Chemistry at Uppsala University in Sweden. His responsibilities include leading formulation, product, and process development activities for biologics and therapeutic vaccines. He earned his PhD in chemical engineering from Kansas State University. He has more than 25 years of industrial experience and has published more than 50 peer-reviewed articles with emphasis on the colloidal and physical chemistry of macromolecules. He also holds four patents. He is involved in several professional groups through the American Association of Pharmaceutical Scientists and the USP, was chair of the Protein Aggregation and Immunogenicity Focus group, and is a frequently invited speaker at various conferences and symposia.

Inhaltsangabe

PRINCIPLES OF BIOPHARMACEUTICAL INFORMATICS. Biopharmaceutical Informatics:
Applications of Computation in Biologic Drug Development. Computational
Methods in the Optimization of Biologic Modalities. Understanding,
Predicting, and Mitigating the Impact of Posttranslational Physiochemical
Modifications, Including Aggregation, on the Stability of Biopharmaceutical
Drug Products. Preclinical Immunogenicity Risk Assessment of
Biotherapeutics. Application of Mechanistic Pharmacokinetic-Pharmacodynamic
Modeling toward the Development of Biologics. Challenges in
High-Concentration Biopharmaceutical Drug Delivery: A Modeling Perspective.
DEVELOPABILITY PRACTICES IN THE BIOPHARMACEUTICAL INDUSTRY. Best Practices
in Assessment of Developability of Biopharmaceutical Candidates. Best
Practices in Developability Assessments of Therapeutic Protein Candidates
in the Biopharmaceutical Industry. Best Practices in Assessing the
Developability of Biopharmaceutical Candidates. Developability Assessment
Workflows to De-Risk Biopharmaceutical Development.